Fortrea Holdings Inc. Stock price

Equities

FTRE

US34965K1079

Biotechnology & Medical Research

Market Closed - Nasdaq 04:00:00 2024-02-27 pm EST 5-day change 1st Jan Change
37.38 USD +2.41% Intraday chart for Fortrea Holdings Inc. +5.62% +7.11%
Days
Hours
Minutes
Seconds
-40%
on all our subscriptions*
limited-time offer
Enjoy this offer
* See conditions on site
Sales 2023 * 3.11B Sales 2024 * 3.2B Capitalization 3.32B
Net income 2023 * 29M Net income 2024 * 13M EV / Sales 2023 * 1.55 x
Net Debt 2023 * 1.51B Net Debt 2024 * 1.45B EV / Sales 2024 * 1.49 x
P/E ratio 2023 *
115 x
P/E ratio 2024 *
467 x
Employees 19,000
Yield 2023 *
-
Yield 2024 *
-
Free-Float 99.99%
More Fundamentals * Assessed data
Dynamic Chart
1 day+2.41%
1 week+5.62%
Current month+20.74%
1 month+20.89%
3 months+11.42%
6 months+36.08%
Current year+7.11%
More quotes
1 week
36.39
Extreme 36.385
38.47
1 month
30.16
Extreme 30.16
38.47
Current year
29.49
Extreme 29.485
38.47
1 year
24.93
Extreme 24.925
38.47
3 years
24.93
Extreme 24.925
38.47
5 years
24.93
Extreme 24.925
38.47
10 years
24.93
Extreme 24.925
38.47
More quotes
Date Price Change Volume
24-02-27 37.38 +2.41% 857,023
24-02-26 36.5 -0.19% 637,976
24-02-23 36.57 -1.14% 724,723
24-02-22 36.99 +1.70% 1,111,589
24-02-21 36.37 +2.77% 965,889

Delayed Quote Nasdaq, February 27, 2024 at 04:00 pm EST

More quotes
Fortrea Holdings Inc. is a global contract research organization. The Company is a provider of comprehensive Phase I through IV clinical trial management, clinical pharmacology, patient access solutions and other enabling services. The Company’s segments include Clinical Services and Enabling Services. The Company’s global solutions include Clinical Development, Clinical Pharmacology, Drug Development Consulting Services, Device and Diagnostic Development, and Full and Functional Service Provider Models, among others. Its Clinical Development solutions include Early: Phase I/II a, Late: Phase II b/III, Real-World Evidence and Post-Approval Studies, Decentralized Clinical Trials, Data Analysis and Reporting, Clinical Trial Project Management and Monitoring, and Patient Safety and Pharmacovigilance. By therapeutic or specialty areas, it has scientific expertise in cardiovascular, cell and gene therapies, dermatology, diabetes and endocrinology, hepatology, infectious disease, and others.
Calendar
More about the company
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
7
Last Close Price
37.38 USD
Average target price
37.25 USD
Spread / Average Target
-0.35%
Consensus
  1. Stock
  2. Equities
  3. Stock Fortrea Holdings Inc. - Nasdaq
-40% Limited-time offer: Our subscriptions help you unlock the best investment opportunities.
SIGN UP NOW